中山痔疮手术几天可以恢复(中山哪里有治内痔的) (今日更新中)

BEIJING, Jan. 1 (Xinhua) -- President Hu Jintao, along with other Chinese leaders, celebrated the New Year with political advisors Sunday morning in Beijing and delivered an important speech.Hu and the other members of the Standing Committee of the Political Bureau of the Communist Party of China (CPC) Central Committee Wu Bangguo, Wen Jiabao, Jia Qinglin, Li Changchun, Xi Jinping, Li Keqiang, He Guoqiang and Zhou Yongkang attended a tea party held by the National Committee of the Chinese People's Political Consultative Conference (CPPCC).The party was presided over by Jia Qinglin, chairman of the CPPCC National Committee.The leaders were joined by senior members of the central committees of non-Communist parties and the All-China Federation of Industry and Commerce, personages without party affiliation, officials of the central government and representatives from all walks of life and all ethnic groups in Beijing.

BEIJING, Nov. 24 (Xinhua) -- China's Supreme People's Court vowed to harshly crack down on bribery, abuse of power and malpractice in food safety cases as such illegalities have become top concerns for Chinese people.Chinese courts at all levels had heard 173 cases and sentenced 255 people in relation to the production and sale of unsafe food in the first ten months of this year, Sun Jungong, spokesman of the Supreme People's Court (SPC), said Thursday."China has seen a growing number of food safety cases in recent years with increasing difficulties for investigation," Sun said.According to the SPC, Chinese courts handled 84 food safety cases in 2008, and 148 and 119 cases in 2009 and 2010, respectively. The number of food safety violators sentenced in the past three years totaled 101, 208 and 162, respectively.The SPC also promulgated four typical food safety illegalities exposed in recent years.In the latest food safety scandal, four people in central China's Henan province were prosecuted for the crime of "endangering public security by using dangerous means" in July after they were found to have produced and sold clenbuterol, a poisonous feed additive that pig farms use to boost the output of lean meat.The spokesman said the SPC will strengthen cooperation with police and procuratorial organs to improve the efficiency of dealing with, and preventing food safety crimes.

BAIKONUR, Kazakhstan, Nov. 9 (Xinhua) -- Russia's Phobos-Grunt probe and China's Yinghuo-1 satellite were launched from the Baikonur cosmodrome in Kazakhstan on a Zenit-2SB rocket at 00:16 am Moscow time Wednesday (2016 GMT Tuesday).The main aim of the Phobos-Grunt unmanned mission is to bring back the first ever soil sample from Phobos, the larger of Mars' two moons.Russia had spent about 5 billion rubles (about 161 million U.S. dollars) preparing for the three-year mission, which would include drilling Phobos' surface and returning 200 grams of soil back to Earth, according to Russian state space agency Roscosmos.The mission would also collect bacteria samples for two Russian and one U.S. biological experiments.In the meantime, China's first Mars probe Yinghuo will go into orbit around Mars and observe the planet itself.Phobos-Grunt is planned to reach Mars in 2012, then deploy its lander for Phobos in 2013 and return the soil sample back to Earth in August 2014.The Chinese probe, which would not land on Mars nor return to the Earth, is expected stay permanently in the space and communicate with the ground control directly via satellites.The Chinese probe is 75 cm long, 75 cm wide and 60 cm high. It weighs 115 kilograms and was designed for a two-year life to discover why water disappeared from Mars and shed light on other environmental changes on the planet.Victor Khartov, chief designer and director general of Lavochkin Research & Production Association, told Xinhua that the three-year mission is highly complicated."It consists of eight sub-missions: launch, travel to Mars vicinities, separation with the Chinese probe YH-1, landing on Phobos, soil collection, launch from Phobos, way back to the Earth, and final landing. Failure of any one of them could doom the entire project," he said.The launch of Phobos-Grunt and Yinghuo-1, originally scheduled for October 2009 on a Russian carrier rocket, has been postponed until 2011 due to "technical reasons" on the Russian side.

WASHINGTON, Nov. 10 (Xinhua) -- NASA's car-sized Mars rover Curiosity, which will examine one of the most intriguing areas on the Red Planet, is in final preparations for a launch from Florida 's Space Coast at 10:25 a.m. EST (15:25 GMT) on Nov. 25, the U.S. space agency announced on Thursday.Curiosity is about twice as long and more than five times as heavy as any previous Mars rover. Its 10 science instruments include two for ingesting and analyzing samples of powdered rock delivered by the rover's robotic arm. It is now sitting atop an Atlas V rocket awaiting liftoff from Cape Canaveral Air Force Station."Preparations are on track for launching at our first opportunity," said Pete Theisinger, Mars Science Laboratory project manager at NASA's Jet Propulsion Laboratory. "If weather or other factors prevent launching then, we have more opportunities through Dec. 18."Scheduled to land on the Mars in Aug. 2012, the one-ton rover will examine Gale Crater during a nearly two-year prime mission. Curiosity will land near the base of a layered mountain three miles (five kilometers) high inside the crater. The rover will investigate whether environmental conditions ever have been favorable for development of microbial life and preserved evidence of those conditions.

WASHINGTON, Nov. 18 (Xinhua) -- The U.S. Food and Drug Administration (FDA) on Friday revoked its approval of Avastin for treating the breast cancer after concluding that the drug has not been shown to be safe and effective for that use.Avastin will still remain on the market as an approved treatment for certain types of colon, lung, kidney and brain cancer."After reviewing the available studies it is clear that women who take Avastin for metastatic breast cancer risk potentially life-threatening side effects without proof that the use of Avastin will provide a benefit, in terms of delay in tumor growth, that would justify those risks," FDA Commissioner Margaret Hamburg said in a statement. "Nor is there evidence that use of Avastin will either help them live longer or improve their quality of life. "Avastin's risks include severe high blood pressure; bleeding and hemorrhaging; heart attack or heart failure; and the development of perforations in different parts of the body such as the nose, stomach, and intestines.Avastin was approved for metastatic breast cancer in February 2008 under the FDA's accelerated approval program, which allows a drug to be approved based on data that are not sufficiently complete to permit full approval. After the approval, the drug's sponsor, Genentech, completed two additional clinical trials and submitted the data from those studies to the FDA. These data showed only a small effect on tumor growth without evidence that patients lived any longer or had a better quality of life compared to taking standard chemotherapy alone -- not enough to outweigh the risk of taking the drug.FDA's Center for Drug Evaluation and Research, which is responsible for the approval of this drug, ultimately concluded that the results of these additional studies did not justify continued approval and notified Genentech it was proposing to withdraw approval of the indication.Genentech did not agree with the Center's evaluation of the data and, following the procedures set out in FDA regulations, requested a hearing on the Center's withdrawal proposal, with a decision to be made by the Commissioner. That two-day hearing, which took place June 28-29, included recommendations from the FDA 's Oncologic Drugs Advisory Committee, voting 6-0 in favor of withdrawing approval of Avastin's breast cancer indication.

来源：资阳报